Avalyn Pharma (AVLN) Financials: Revenue & Earnings
AVLN$25.60-0.23 -0.89%
$1.13B
Market Cap
-20.19
P/E
—
Forward P/E
71
Score
Avalyn Pharma (AVLN) Financials: Revenue & Earnings
AVLN price $25.60 -0.23 -0.89%
- Ticker
- AVLN
- Price
- $25.60
- Change
- -0.23 -0.89%
- Market cap ?
- $1.13B
- P/E ?
- -20.19
- Dividend yield ?
- 0.00%
- Beta ?
- -1.13
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 71
- Value
- 64
- Quality
- 50
- Growth
- 100
Stocklytics score rationale: value 64, quality 50, growth 100.
Financials
| 2025 |
|---|
| 0 |
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate…
Fair value
AVLN fair value Not meaningful. Price $25.60.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.
Not meaningful
Earnings
| Date | EPS actual | EPS estimate | Revenue | Revenue estimate |
|---|---|---|---|---|
| 2026-11-11 | — | -0.71 | — | — |
| 2026-08-12 | -0.98 | -0.78 | — | — |
| 2026-06-03 | -21.83 | -5.98 | — | — |
Dividends
Yield 0.00%. Payout ratio 0.00%. Frequency —.
Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.
| Ex-date | Dividend | Record | Payment | Frequency |
|---|---|---|---|---|
| No data yet. | ||||
Insider trades
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-09-15 | Meyer Robert J. | Buy | 31.18K | $34.28 | 1.07M |
| 2026-09-15 | Meyer Robert J. | Other | 0 | — | — |
Institutional holders
Latest filed quarter: Q2 2026.
Institutions holding: 95. Ownership 106.36%.
| Holder | Shares | Change | Change % | Value |
|---|---|---|---|---|
| FMR LLC | 5.84M | New | New | 192.10M |
| NOVO HOLDINGS A/S | 3.88M | New | New | 127.84M |
| SR ONE CAPITAL MANAGEMENT, LP | 3.31M | New | New | 108.92M |
| PERCEPTIVE ADVISORS LLC | 2.68M | New | New | 88.07M |
| MONTANOVA CAPITAL, LLC | 2.50M | New | New | 82.40M |
| NVP ASSOCIATES, LLC | 2.27M | New | New | 74.68M |
| WELLINGTON MANAGEMENT GROUP LLP | 2.20M | New | New | 72.49M |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.74M | New | New | 57.12M |
| CATALIO CAPITAL MANAGEMENT, LP | 1.68M | New | New | 55.17M |
| T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 1.60M | New | New | 52.76M |
| EVENTIDE ASSET MANAGEMENT, LLC | 1.38M | New | New | 45.28M |
| BELLEVUE GROUP AG | 1.35M | New | New | 44.44M |
| BLACKROCK, INC. | 977.26K | New | New | 32.17M |
| PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC | 966.79K | New | New | 31.83M |
| CITADEL ADVISORS LLC | 959.10K | New | New | 31.57M |
| ANDERA PARTNERS | 929.82K | New | New | 30.61M |
| JENNISON ASSOCIATES LLC | 812.75K | New | New | 26.76M |
| BRAIDWELL LP | 801.39K | New | New | 26.38M |
| TPG GP A, LLC | 773.07K | New | New | 25.45M |
| VANGUARD CAPITAL MANAGEMENT LLC | 739.77K | New | New | 24.35M |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 731.00K | New | New | 24.06M |
| ROCK SPRINGS CAPITAL MANAGEMENT LP | 662.92K | New | New | 21.82M |
| GEODE CAPITAL MANAGEMENT, LLC | 434.65K | New | New | 14.31M |
| SOLEUS CAPITAL MANAGEMENT, L.P. | 419.00K | New | New | 13.79M |
| INFINITUM ASSET MANAGEMENT, LLC | 411.38K | New | New | 13.54M |
Earnings and financials
Avalyn Pharma Inc. Common Stock (AVLN) trades at $25.60, with a market cap of $1.13B and a trailing P/E of -20.19. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Financials
| 2025 |
|---|
| 0 |
Insights · Dividends · Forecast · Financials · Learn